#China #Beijing #LakeShore Biopharma #Extraordinary Meeting #Oceanpine Skyline

LakeShore Biopharma Sets Date for Extraordinary General Meeting

LakeShore Biopharma Co., Ltd, a key player in the global biopharmaceutical field, has announced that it will hold an extraordinary general meeting of shareholders (EGM) on February 12, 2026. The meeting is scheduled to begin at 11 a.m. (Beijing time) and will be held at Unit 1301, Tower 1, China Central Place, on Jianguo Road, in Chaoyang District, Beijing, China.

The primary focus of the EGM will be to discuss and vote on critical matters relating to the company's previously announced merger agreement with Oceanpine Skyline Inc. and its wholly owned subsidiary, Oceanpine Merger Sub Inc., which is expected to significantly reshape the company's future.

Merger Agreement Details

The merger agreement, dated November 4, 2025, outlines a plan where Oceanpine Merger Sub will merge with LakeShore Biopharma, effectively making the latter a wholly owned subsidiary of Oceanpine. Following the merger, LakeShore will cease to exist as a public entity, transitioning into a privately held company. This move will also result in the delisting of LakeShore's ordinary shares and associated warrants from public trading systems, including the OTC Pink tier.

This transition, if approved, is anticipated to create a streamlined operation for LakeShore Biopharma, focusing its efforts on developing innovative vaccines and therapeutic biologics aimed at combating infectious diseases and cancer—a mission central to the company's core values.

Shareholder Involvement

Shareholders who are on record as of January 16, 2026, at 5 p.m. (Cayman Islands time) will have the opportunity to participate in the EGM. They are encouraged to engage in discussions surrounding the merger proposals and to vote on the initiatives presented by the company's board of directors. The board has unanimously endorsed the proposed merger, emphasizing the potential advantages it could bring, not only to the company but also to its shareholders and the communities it serves.

Importance of the Meeting

The EGM is a pivotal moment for LakeShore Biopharma as it navigates this transformative phase. Shareholders are invited to review comprehensive materials related to the meeting, including the merger agreement and proxy statements filed with the U.S. Securities and Exchange Commission (SEC), to ensure they are well-informed.

LakeShore Biopharma's commitment to pioneering advancements in the biopharmaceutical sector strengthens its position as a competitive player in the international market. The unique PIKA® immunomodulating technology platform developed by the company has already shown promise in targeting viruses such as Rabies, Hepatitis B, and Influenza.

About LakeShore Biopharma

Previously known as YS Biopharma, LakeShore Biopharma operates in critical markets including China, Singapore, and the Philippines. It is firmly committed to enhancing human health through innovative biological therapies that bring hope to patients dealing with life-threatening diseases. This meeting marks a major step in the company’s evolution, aiming to provide the strategic direction necessary for future success.

In conclusion, attendance at the EGM is crucial for all shareholders. They are strongly urged to review the relevant materials thoroughly and cast their votes on the critical issues that will shape LakeShore Biopharma's future.

For additional inquiries about the meeting and the merger agreement, shareholders can contact LakeShore Biopharma's Investor Relations Department directly via phone or email.